Composition for sustained release of non-aggregated erythropoietin
First Claim
1. A composition for the sustained release of biologically active, non-aggregated erythropoietin from a polymeric matrix, comprising:
- a) a biodegradable polymer; and
b) particles of biologically active, aggregation-stabilized erythropoietin, wherein said particles include erythropoietin in contact with a salting-out salt, and wherein said erythropoietin particles are dispersed within the polymeric matrix.
0 Assignments
0 Petitions
Accused Products
Abstract
A composition, and methods of forming and using said composition, for the sustained release of non-aggregated, biologically active, erythropoietin (EPO). The sustained release composition of this invention comprises a polymeric matrix of a biocompatible polymer and particles of biologically active, aggregation-stabilized EPO, wherein said particles are dispersed within the biocompatible polymer.
The method of the invention for producing a composition for the sustained release of biologically active EPO includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, aggregation-stabilized EPO in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said EPO particles.
The method for using a composition of the invention is a method for providing a therapeutically effective blood level of biologically active, non-aggregated erythropoietin in a subject for a sustained period. In this method, a subject is administered an effective dose of the sustained release composition of the present invention.
-
Citations
18 Claims
-
1. A composition for the sustained release of biologically active, non-aggregated erythropoietin from a polymeric matrix, comprising:
-
a) a biodegradable polymer; and
b) particles of biologically active, aggregation-stabilized erythropoietin, wherein said particles include erythropoietin in contact with a salting-out salt, and wherein said erythropoietin particles are dispersed within the polymeric matrix. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 16, 17, 18)
-
-
9. A method for forming a composition for the sustained release of biologically active erythropoietin from a polymeric matrix, comprising the steps of:
-
a) dissolving a biodegradable polymer in a polymer solvent to form a polymer solution;
b) dispersing particles of biologically active, aggregation-stabilized erythropoietin in the polymer solution, wherein said particles include erythropoietin in contact with a salting-out salt; and
c) solidifying the polymer to form a polymeric matrix containing a dispersion of said erythropoietin particles. - View Dependent Claims (10, 11, 12, 13, 14)
-
-
15. A method for forming microparticles for the sustained release of biologically active, non-aggregated erythropoietin, comprising the steps of:
-
a) mixing biologically active erythropoietin with a salting-out salt and with a buffer, wherein said buffer has a pH between about 4 and about 8, to form an aggregation-stabilizing mixture; and
b) lyophilizing said mixture to form biologically active, aggregation-stabilized erythropoietin;
c) dispersing particles of biologically active, aggregation-stabilized erythropoietin in a polymer solution to form a dispersion;
d) freezing droplets of the dispersion to form microparticles; and
e) contacting the microparticles with a liquid non-solvent, which is miscible with the polymer solvent, whereby the polymer solvent is extracted from the microparticles, thereby forming microparticles for the sustained release of biologically active, non-aggregated erythropoietin.
-
Specification